Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease

Dosing has been completed ahead of schedule in a pivotal phase 2/3 clinical trial evaluating OCU410ST, an investigational gene therapy for Stargardt disease, according to a company announcement from Ocugen, Inc.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy. Stargardt disease is the most common inherited macular dystrophy, typically presenting in childhood or adolescence and characterized by progressive central vision loss due to retinal pigment epithelium (RPE) and photoreceptor degeneration.^1,2

Trial design and end points

GARDian3 is a multicenter, randomized, masked, phase 2/3 confirmatory trial enrolling 63 participants with genetically or clinically diagnosed Stargardt disease. Patients were randomized to receive a one-time subretinal injection of OCU410ST in the eye with worse visual acuity or to an untreated control group.

The primary endpoint is reduction in the growth of atrophic retinal lesions at 12 months, a structural outcome increasingly used in inherited retinal disease trials given the slow and variable decline in visual acuity. Secondary endpoints include changes in best-corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA), while exploratory measures include preservation of the ellipsoid zone (EZ) on optical coherence tomography, a biomarker associated with photoreceptor integrity and visual function.³

An interim analysis is planned for the third quarter of 2026 after 24 treated patients complete 8 months of follow-up. One-year data are expected to support a planned Biologics License Application (BLA), according to the sponsor.

The company reports no serious adverse events or adverse events of special interest to date, including intraocular inflammation, vasculitis, or choroidal neovascularization. However, these findings have not yet been independently verified or published in a peer-reviewed setting.

Clinical context and unmet need

Stargardt disease is caused by biallelic mutations in the ABCA4 gene, leading to accumulation of toxic bisretinoids such as lipofuscin in the RPE, ultimately resulting in progressive macular atrophy.¹ Disease prevalence is estimated at approximately 1 in 8,000 to 10,000 individuals, with significant heterogeneity in onset and progression.²

There are currently no approved therapies for Stargardt disease in the United States or Europe. Management is limited to visual rehabilitation and counseling, underscoring the need for disease-modifying approaches.⁴ Prior investigational strategies have included visual cycle modulators, complement inhibitors, and gene replacement therapies, although none have demonstrated definitive efficacy in late-stage trials to date.

Mechanism and platform considerations

OCU410ST is an adeno-associated virus serotype 5 (AAV5)-based gene therapy delivering the RORA (RAR-related orphan receptor A) gene. Unlike traditional gene replacement approaches that target a specific mutation, this “modifier gene therapy” is designed to regulate multiple downstream pathways implicated in retinal degeneration, including oxidative stress, inflammation, and complement activation.

This mutation-agnostic approach may be particularly relevant for Stargardt disease, which involves a large and highly polymorphic gene (ABCA4) that presents challenges for conventional gene replacement due to vector packaging limits.⁵ Similar modifier strategies are under investigation in other retinal diseases but remain largely unproven in late-stage trials.

Early-phase data and interpretation

The company cites findings from a phase 1 study (GARDian1), in which treated eyes demonstrated slower atrophic lesion growth compared with untreated fellow eyes at 12 months, along with modest improvements in BCVA. However, these results are based on a small sample size and intra-patient comparisons, limiting generalizability.

While structural endpoints such as lesion growth are increasingly accepted in retinal trials, their correlation with functional outcomes remains an area of ongoing investigation. Improvements in visual acuity may take longer to manifest, particularly in slowly progressive diseases such as Stargardt.³

Limitations and next steps

The GARDian3 trial’s relatively small sample size and use of an untreated control group may introduce variability, particularly given the heterogeneity of disease progression. Additionally, the absence of sham treatment may complicate masking and introduce bias in subjective endpoints.

If successful, OCU410ST could represent one of the first disease-modifying therapies for Stargardt disease. However, clinical benefit—particularly functional improvement—remains to be demonstrated in a controlled setting.

References

1. National Eye Institute. Stargardt disease. Accessed April 1, 2026. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease

2. Lambertus S, van Huet RAC, Bax NM, et al. Early-onset Stargardt disease: phenotypic and genotypic characteristics. Ophthalmology. 2015;122(2):335-344. https://doi.org/10.1016/j.ophtha.2014.08.032

3. Strauss RW, Ho A, Muñoz B, et al. Progression of Stargardt disease as determined by fundus autofluorescence. Invest Ophthalmol Vis Sci. 2016;57(10):OCT517-OCT526. https://doi.org/10.1167/iovs.15-18724

4. American Academy of Ophthalmology. Inherited retinal diseases PPP. Accessed April 1, 2026. https://www.aao.org/preferred-practice-pattern/inherited-retinal-diseases-ppp

5. Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6(2):194-211. https://doi.org/10.1002/emmm.201302948

6. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV gene therapy). Lancet. 2017;390(10097):849-860. https://doi.org/10.1016/S0140-6736(17)31868-8